🛑 Stop Wasting Intake on “Headache” Calls (Depo-Provera Solution)

The Depo-Provera MDL (3140) is moving fast. The science is strong (5.6x risk of Meningioma), and the defendant is solvent (Pfizer).

But if you are buying raw leads, you are likely burning your intake team out on non-qualifying injuries.

Stop buying “maybes.” Start buying Retainers.

At Mohr Marketing, we utilize the Compliance Shield protocol to rigorously vet potential claimants against strict compensability criteria⁶. We do the heavy lifting before the lead ever hits your phone lines.

Our Depo-Provera Signed Case Criteria:

✅ Confirmed Injury: Intracranial Meningioma (Imaging verified).

✅ Verified Usage: 12+ Months of consistent injections (Cumulative Dose).

✅ TCPA Compliant: 100% Documented Consent via TrustedForm/Jornaya7.

We deliver plaintiffs who aren’t just “leads”—they are qualified clients with verified fact patterns ready for litigation.

Ready to fill your docket with valid cases?

Partner with Mohr Marketing to secure high-quality, compliant plaintiffs for the Depo-Provera MDL.

Ready to build your Depo-Provera inventory?

Contact Mohr Marketing to deploy the Compliance Shield today.

Click Here Get a Custom Quote

Let’s discuss your specific needs and how our Compliance Program, AI Lead Generation Technology, digital marketing, and mass tort cases can help you achieve your growth goals.

www.mohrmktg.com 

Best Wishes,
Sue Mohr

Summary

Article Name

Get Signed, Vetted Meningioma Cases with the Compliance Shield

Description

The Depo-Provera MDL (3140) is moving fast. The science is strong (5.6x risk of Meningioma), and the defendant is solvent (Pfizer).

Author

Susan Mohr

Publisher Name

Mohr Marketing, LLC

Publisher Logo